文献速递癫痫

拉莫三嗪与心律失常:目标试验模拟研究

Lamotrigine and Cardiac Arrhythmias: A Target Trial Approach.
PubMed 文献 · Neurology · 2025-06-11

该研究采用目标试验模拟的回顾性队列设计,基于美国Medicare和英国CPRD两个数据库,比较新诊断癫痫患者使用拉莫三嗪与左乙拉西坦后室性心动过速或心室颤动的发生率。结果显示,拉莫三嗪组2年累积发生率略低于左乙拉西坦组,但差异无统计学意义,不支持拉莫三嗪增加心律失常风险的担忧。

要点

  • 拉莫三嗪与左乙拉西坦相比,室速/室颤风险无显著升高。
  • 两个数据库的2年累积发生率绝对差异均较小且无统计学意义。
  • 敏感性分析结果一致,包括不同结局、删失方式和人群。

核心结论

  • 数据不支持拉莫三嗪增加心律失常风险的担忧。

研究设计与样本

  • 采用目标试验模拟的回顾性队列研究,使用美国Medicare(2009-2018)和英国CPRD两个数据库。
  • 纳入首次抗癫痫发作药物处方在首次癫痫诊断或ICD编码之后、且前一年无抗癫痫发作药物使用的患者。
  • Medicare队列共40,554例(拉莫三嗪3,038例,左乙拉西坦37,516例),CPRD队列共13,098例(拉莫三嗪8,694例,左乙拉西坦4,404例)。

主要发现

  • Medicare中位年龄拉莫三嗪组61岁(IQR 44-74),女性60%;左乙拉西坦组74岁(IQR 65-82),女性57%。
  • CPRD中位年龄拉莫三嗪组34岁(IQR 23-53),女性63%;左乙拉西坦组48岁(IQR 29-66),女性50%。
  • 校正后室速/室颤风险比:Medicare为0.73(95% CI 0.50-1.08),CPRD为0.75(95% CI 0.35-1.59)。
  • 2年累积发生率:Medicare拉莫三嗪1.7%(95% CI 1.0%-2.3%) vs 左乙拉西坦2.3%(95% CI 2.1%-2.4%);CPRD拉莫三嗪0.2%(95% CI 0.1%-0.4%) vs 左乙拉西坦0.3%(95% CI 0.2%-0.6%)。
  • 2年绝对差异:Medicare -0.6%(95% CI -1.2% to 0.0%),CPRD -0.1%(95% CI -0.3% to 0.1%)。

关键数值与推荐

  • 主要结局为室性心动过速或心室颤动(VT/VF)。
  • 采用Cox比例风险模型估计风险比和累积发生率曲线。

临床怎么用

  • 对于成人癫痫患者,拉莫三嗪不增加室速/室颤风险,临床可放心使用。

局限性

  • 可能存在残余混杂。
  • 结果不能推广到其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: While lamotrigine is an effective, well-tolerated antiseizure medication (ASM), a recent warning raised the possibility of ventricular arrhythmias. We compared arrhythmia incidence between patients newly treated for seizures with lamotrigine and those with levetiracetam (presumed cardiac-inert control). METHODS: We included patients whose first ASM prescription fill was after the first seizure or epilepsy ICD code in the study period, with no ASM in the previous year. We conducted retrospective cohort studies to emulate a target trial using 2 datasets: (1) 2009-2018 Medicare claims (United States) and (2) Clinical Practice Research Datalink (CPRD), a population-based cohort (United Kingdom). We examined cumulative incidence curves for ventricular tachycardia or fibrillation (VT/VF) from Cox proportional hazard models. RESULTS: We included 40,554 patients (lamotrigine: 3,038; levetiracetam: 37,516) from Medicare and 13,098 (lamotrigine: 8,694; levetiracetam: 4,404) from CPRD. In Medicare, the median (interquartile range) age was 61 (44-74) years and 60% were female in the lamotrigine group vs 74 (65-82) years and 57% female in the levetiracetam group. In CPRD, the median (interquartile range) age was 34 (23-53) years and 63% were female in the lamotrigine group vs 48 (29-66) years and 50% female in the levetiracetam group. After adjusting for demographics, comorbidities, and medication use, the hazard ratio for VT/VF comparing patients whose first ASM was lamotrigine vs levetiracetam was 0.73 (95% CI 0.50-1.08) for Medicare and 0.75 (95% CI 0.35-1.59) for CPRD, with a 2-year cumulative incidence of 1.7% (95% CI 1.0%-2.3%) vs 2.3% (95% CI 2.1%-2.4%) for Medicare and 0.2% (95% CI 0.1%-0.4%) vs 0.3% (95% CI 0.2%-0.6%) for CPRD. In both datasets, lamotrigine showed a slightly but nonsignificantly lower 2-year absolute difference in cumulative incidence of VT/VF compared with levetiracetam (Medicare: -0.6%, 95% CI -1.2% to 0.0%; CPRD: -0.1%, 95% CI -0.3% to 0.1%). Numerous sensitivity analyses modifying the outcome (atrial arrhythmias or any arrhythmias), censorship procedure (further censoring patients on discontinuing their initial ASM akin to a "per-protocol" analysis), or population (patients with existing cardiovascular diagnoses) found similar results. DISCUSSION: These data do not support concerns regarding lamotrigine increasing arrhythmias. Limitations include possible residual confounding and lack of generalizability to other populations. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that lamotrigine compared with levetiracetam did not significantly increase the 2-year cumulative incidence of VT/VF in adult patients with epilepsy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Terman SW, Josephson CB, Goyal P, et al. Lamotrigine and Cardiac Arrhythmias: A Target Trial Approach. Neurology. 2025. PMID: 40499085. doi:10.1212/WNL.0000000000213640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。